|
Title
|
|
|
|
Local treatment of stage IIIA-N2 nonsmall cell lung cancer: surgery and/or radiotherapy
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Purpose of review Controversy exists regarding the optimal treatment of patients with stage IIIA-N2 nonsmall cell lung cancer because of its heterogeneity. Patients are at risk for both local and distant disease relapse after primary local treatment. However, there may be a window of opportunity for surgery, if mediastinal downstaging has been obtained after induction therapy. This manuscript reviews the outcome of patients treated by neo-adjuvant chemotherapy (NA-C) followed by surgery, compared with patients treated with either definitive sequential or concurrent chemoradiotherapy (cCRT), illustrated by a single-centre retrospective case series. Recent findings Of 53 eligible patients, 19 received NA-C and underwent surgical resection, whilst 20 and 14 received concurrent or sequential definitive CRT, respectively. A significant difference in progression-free survival favouring NA-C followed by surgery over both CRT modalities was found. However, this translated only in an overall survival benefit in comparison with sequential definitive CRT. A trend for better outcome was observed in selected surgical patients with single-level mediastinal involvement and complete resection. Our case series results are consistent with the present standard of care of CRT, which restricts surgical resection to carefully selected patients. Immunotherapy will likely change the treatment paradigm. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Current opinion in oncology. - Philadelphia, Pa
| |
|
Publication
|
|
|
|
Philadelphia
:
Lippincott williams & wilkins
,
2020
| |
|
ISSN
|
|
|
|
1040-8746
| |
|
DOI
|
|
|
|
10.1097/CCO.0000000000000596
| |
|
Volume/pages
|
|
|
|
32
:1
(2020)
, p. 54-62
| |
|
ISI
|
|
|
|
000524520800009
| |
|
Pubmed ID
|
|
|
|
31688138
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|